HK1005704A1 - Use of rapamycin and derivative and prodrugs therof in the manufacture of a medicament for inhibiting transplant rejection in mammals - Google Patents

Use of rapamycin and derivative and prodrugs therof in the manufacture of a medicament for inhibiting transplant rejection in mammals

Info

Publication number
HK1005704A1
HK1005704A1 HK98104904A HK98104904A HK1005704A1 HK 1005704 A1 HK1005704 A1 HK 1005704A1 HK 98104904 A HK98104904 A HK 98104904A HK 98104904 A HK98104904 A HK 98104904A HK 1005704 A1 HK1005704 A1 HK 1005704A1
Authority
HK
Hong Kong
Prior art keywords
transplant rejection
rapamycin
inhibiting
mammals
medicament
Prior art date
Application number
HK98104904A
Other languages
English (en)
Inventor
Roy Calne
Original Assignee
Roy Calne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23425763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1005704(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roy Calne filed Critical Roy Calne
Publication of HK1005704A1 publication Critical patent/HK1005704A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK98104904A 1989-06-06 1998-06-04 Use of rapamycin and derivative and prodrugs therof in the manufacture of a medicament for inhibiting transplant rejection in mammals HK1005704A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/362,354 US5100899A (en) 1989-06-06 1989-06-06 Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof

Publications (1)

Publication Number Publication Date
HK1005704A1 true HK1005704A1 (en) 1999-01-22

Family

ID=23425763

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104904A HK1005704A1 (en) 1989-06-06 1998-06-04 Use of rapamycin and derivative and prodrugs therof in the manufacture of a medicament for inhibiting transplant rejection in mammals

Country Status (18)

Country Link
US (5) US5100899A (de)
EP (1) EP0401747B1 (de)
JP (1) JP2969150B2 (de)
KR (1) KR0160957B1 (de)
AT (1) ATE135215T1 (de)
AU (1) AU638253B2 (de)
CA (1) CA2018287C (de)
DE (2) DE10199045I2 (de)
DK (1) DK0401747T3 (de)
ES (1) ES2085299T3 (de)
GR (1) GR3019792T3 (de)
HK (1) HK1005704A1 (de)
HU (1) HU206974B (de)
IL (1) IL94634A (de)
LU (1) LU90831I2 (de)
MX (1) MX173183B (de)
NL (1) NL300056I2 (de)
SG (1) SG44632A1 (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5358944A (en) * 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
KR100237715B1 (ko) * 1991-04-26 2000-02-01 후지야마 아키라 안과질환에 대한 마크로라이드 화합물의 용도
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
JPH06502659A (ja) * 1991-05-31 1994-03-24 ファイザー　インク 免疫抑制剤としてのラパマイシンプロドラッグの使用
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
GB9125660D0 (en) * 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5221740A (en) * 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
WO1993014780A1 (en) * 1992-01-28 1993-08-05 Abraham Karpas The use of a compound for the manufacture of a medicament for the treatment of hiv infection
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
EP0562853B1 (de) 1992-03-27 1996-06-05 American Home Products Corporation 29-Demethoxyrapamycin zur Induktion der Immunosuppression
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
JP2741285B2 (ja) * 1992-05-22 1998-04-15 千寿製薬株式会社 緑内障治療剤
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
CA2161101A1 (en) 1993-04-23 1994-11-10 Eduardo Gonzalez Rapamycin conjugates and antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
CA2164641A1 (en) * 1993-06-07 1994-12-22 Dinah S. Singer Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
WO1995011992A1 (en) * 1993-10-27 1995-05-04 The Regents Of The University Of California Antiviral compounds
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5756453A (en) * 1994-08-03 1998-05-26 Cell Therapeutics, Inc. Use of angiogenic lipids for vascularizing tissue
US5798386A (en) * 1994-08-03 1998-08-25 Cell Therapeutics, Inc. Angiogenic lipid formulations
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
CA2238029A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
FR2770526B1 (fr) 1997-11-04 2000-01-14 Atochem Elf Sa Dispersions aqueuses stables a base de polymeres hydrosolubles contenant un dispersant cationique comportant des motifs hydrophobes
KR100312454B1 (ko) * 1998-03-27 2001-11-14 김용규 토토마이세틴을 생산하는 스트렙토마이세스 속 미생물 및 그로부터 생산된 토토마이세틴을 유효성분으로 함유하는 면역억제제
US6096731A (en) * 1998-06-24 2000-08-01 Institute For Drug Research, Inc. Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1214293A1 (de) 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Nicht-peptidische cyclophilin bindende verbindungen und ihre verwendung
AU2001259691B2 (en) 2000-05-12 2006-02-16 Genzyme Corporation Modulators of TNF-alpha signaling
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
US20100184732A1 (en) * 2000-09-15 2010-07-22 Mcdonald George Method of long-term treatment of graft-versus-host disease using topical active corticosteroids
CA2421485A1 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
MXPA03006666A (es) 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2003018574A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
AU2002363318B2 (en) * 2001-10-25 2008-09-11 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7026330B2 (en) * 2002-05-30 2006-04-11 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
DK1553940T3 (da) * 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
AU2003291134A1 (en) 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
UA80756C2 (en) * 2003-04-22 2007-10-25 Wyeth Corp Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
US20060084672A1 (en) * 2004-10-20 2006-04-20 The Hospital For Sick Children Method for modification of y-secretase activity through inhibition of Fkbp13
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
PL1848431T3 (pl) 2005-02-09 2016-08-31 Santen Pharmaceutical Co Ltd Ciekłe formulacje do leczenia chorób lub stanów
US20060257450A1 (en) * 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US7189582B2 (en) 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
EP1930415A4 (de) * 2005-09-30 2009-05-13 Univ Kyoto Entwicklung eines screening-verfahrens für eine zur verbesserung der produktion einer regulatorischen t-zelle fähige verbindung und verfahren zur produktion einer regulatorischen t-zelle unter verwendung eines immunsuppressiven makrolidantibiotikums
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt) * 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
US7943775B2 (en) * 2006-06-21 2011-05-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Small molecules for imaging protein-protein interactions
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
US20090054334A1 (en) * 2007-05-23 2009-02-26 Mutz Mitchell W Combinatorial improvement of bifunctional drug properties
US20090053245A1 (en) * 2007-05-29 2009-02-26 Mutz Mitchell W Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood
US20090068266A1 (en) * 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US20100284993A1 (en) * 2007-10-24 2010-11-11 Mutz Mitchell W Enhancing the Efficacy of Anti-Infective Therapeutics
CA2743491C (en) 2008-11-11 2016-10-11 Zelton Dave Sharp Inhibition of mammalian target of rapamycin
US20100268187A1 (en) * 2009-04-17 2010-10-21 Ranbaxy Laboratories Limited Packaging for sirolimus and composition thereof
WO2010132233A1 (en) 2009-05-13 2010-11-18 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
US10704096B2 (en) 2009-07-07 2020-07-07 University Of Southern California Biomarkers for the early detection of autoimmune diseases
HUE052213T2 (hu) 2009-11-06 2021-04-28 Univ Leland Stanford Junior Grafitkilökõdés nem invazív diagnosztizálása szervátültetett betegekben
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
US9687523B2 (en) * 2010-02-04 2017-06-27 University Of Southern California Compositions and methods for the treatment of sjörgren's syndrome
WO2011128910A2 (en) 2010-03-02 2011-10-20 Rpg Life Sciences Limited A drug delivery solid dosage formulation of sirolimus
WO2011135580A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
US9606117B2 (en) 2011-01-13 2017-03-28 University Of Southern California Bioassay for the early detection of autoimmune diseases
EP2594260A1 (de) 2011-11-18 2013-05-22 LEK Pharmaceuticals d.d. Feststoffpräparate mit Sirolimus mit erwünschter Bioverfügbarkeit und Herstellungsverfahren dafür
US9365880B2 (en) 2012-04-12 2016-06-14 Natco Pharma Limited Fermentation process for the production of rapamycin
EP2705856A1 (de) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Verbindungen zur Behandlung von neurodegenerativen Erkrankungen
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2968281B1 (de) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor-hemmer zur vorbeugung von darmpolypenwachstum
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
AU2017213630B2 (en) 2016-02-04 2022-05-12 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof
EP3411032B1 (de) * 2016-02-04 2020-09-30 The Johns Hopkins University Rapadocine, inhibitoren des äquilibrierungsnukleosidtransporters 1 und verwendungen davon
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP7051721B2 (ja) 2016-06-30 2022-04-11 デュレクト コーポレーション デポー製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4316688A (en) * 1980-01-02 1982-02-23 Milton Roskelley Reinforcing removable post pocket tie-down
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin

Also Published As

Publication number Publication date
HU206974B (en) 1993-03-01
US5308847A (en) 1994-05-03
US5461058A (en) 1995-10-24
DE69025803D1 (de) 1996-04-18
HUT54047A (en) 1991-01-28
DE10199045I2 (de) 2006-07-13
EP0401747A2 (de) 1990-12-12
DE69025803T2 (de) 1996-07-25
NL300056I2 (nl) 2002-04-02
ES2085299T3 (es) 1996-06-01
ATE135215T1 (de) 1996-03-15
HU903487D0 (en) 1990-12-28
MX173183B (es) 1994-02-07
SG44632A1 (en) 1997-12-19
IL94634A0 (en) 1991-04-15
AU638253B2 (en) 1993-06-24
DE10199045I1 (de) 2003-06-05
DK0401747T3 (da) 2004-03-08
EP0401747B1 (de) 1996-03-13
JPH0373158A (ja) 1991-03-28
CA2018287A1 (en) 1990-12-06
KR910000169A (ko) 1991-01-29
CA2018287C (en) 2001-11-20
KR0160957B1 (ko) 1998-12-01
US5212155A (en) 1993-05-18
EP0401747A3 (de) 1991-07-03
IL94634A (en) 1996-03-31
LU90831I2 (fr) 2001-11-12
AU5686590A (en) 1991-01-31
US5403833A (en) 1995-04-04
NL300056I1 (nl) 2001-12-01
US5100899A (en) 1992-03-31
GR3019792T3 (en) 1996-07-31
JP2969150B2 (ja) 1999-11-02

Similar Documents

Publication Publication Date Title
HK1005704A1 (en) Use of rapamycin and derivative and prodrugs therof in the manufacture of a medicament for inhibiting transplant rejection in mammals
SI1208847T1 (sl) Farmacevtski sestavki za zdravljenje stanj zavračanja transplantatov in avtoimunskih ali vnetnih stanj
ES2116415T3 (es) Metodo para tratar la enfermedad de crohn, la colitis ulcerosa o la proctitis ulcerosa.
PH31263A (en) Methods of inhibiting vascular smooth muscle cell proliferation and restinosis.
UA41355C2 (uk) Засіб для лікування нейро-сніду
WO2002100148A3 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
ES2133289T3 (es) Aumento en los niveles de glutation con glutamina.
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
HU901516D0 (en) The use of s-adenosile-methionine in the treatment of pancreatitis, and in preventing the natural rejection of transplanted pancreas
CA2385312A1 (en) Compositions and methods for preventing and treating transplant rejection
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
EP0544802A4 (en) Methods and compositions for treating t-cell mediated diseases
SG47465A1 (en) Inhibition of allograft & concordant xenograft rejection
HUP9900601A2 (hu) Benzopirán-származékok allograftkilökődés megelőzésére
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100604